The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
-
BUSINESS MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
-
BUSINESS Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
February 5, 2021
-
BUSINESS Takeda to Begin Japan Trial for Novavax Vaccine as Early as Feb. 20
February 5, 2021
-
BUSINESS Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
-
REGULATORY Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
-
BUSINESS Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
February 4, 2021
-
ORGANIZATION PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
-
REGULATORY Japan Moves Up Vaccine Rollout Target to Mid-February, PAFSC Review on Feb. 12?
February 3, 2021
-
INTERVIEW Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
-
BUSINESS Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
-
BUSINESS FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
-
REGULATORY MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
-
BUSINESS JCR to Make 90 Million Doses of AstraZeneca Coronavirus Vaccine in Japan
January 29, 2021
-
BUSINESS Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
-
REGULATORY Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
-
REGULATORY Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
-
REGULATORY MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
-
BUSINESS Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
-
BUSINESS Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…